These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 25675992)

  • 1. Evaluating Response to High-Dose 13.3 mg/24 h Rivastigmine Patch in Patients with Severe Alzheimer's Disease.
    Farlow MR; Sadowsky CH; Velting DM; Meng X; Islam MZ
    CNS Neurosci Ther; 2015 Jun; 21(6):513-9. PubMed ID: 25675992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
    Farlow MR; Grossberg GT; Meng X; Olin J; Somogyi M
    Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 24-Week, Open-Label Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of 13.3 mg/24 h Rivastigmine Patch in Patients With Severe Alzheimer Disease.
    Farlow MR; Grossberg GT; Sadowsky CH; Meng X; Velting DM
    Alzheimer Dis Assoc Disord; 2015; 29(2):110-6. PubMed ID: 25437301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease.
    Grossberg GT; Olin JT; Somogyi M; Meng X
    Int J Clin Pract; 2011 Apr; 65(4):465-71. PubMed ID: 21309961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease.
    Articus K; Baier M; Tracik F; Kühn F; Preuss UW; Kurz A
    Int J Clin Pract; 2011 Jul; 65(7):790-6. PubMed ID: 21645184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rivastigmine Patch in Chinese Patients with Probable Alzheimer's disease: A 24-week, Randomized, Double-Blind Parallel-Group Study Comparing Rivastigmine Patch (9.5 mg/24 h) with Capsule (6 mg Twice Daily).
    Zhang ZX; Hong Z; Wang YP; He L; Wang N; Zhao ZX; Zhao G; Shang L; Weisskopf M; Callegari F; Strohmaier C
    CNS Neurosci Ther; 2016 Jun; 22(6):488-96. PubMed ID: 27012596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule.
    Winblad B; Cummings J; Andreasen N; Grossberg G; Onofrj M; Sadowsky C; Zechner S; Nagel J; Lane R
    Int J Geriatr Psychiatry; 2007 May; 22(5):456-67. PubMed ID: 17380489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer's dementia.
    Farlow MR; Grossberg GT; Sadowsky CH; Meng X; Somogyi M
    CNS Neurosci Ther; 2013 Oct; 19(10):745-52. PubMed ID: 23924050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysis.
    Cummings JL; Ferris SH; Farlow MR; Olin JT; Meng X
    Dement Geriatr Cogn Disord; 2010; 29(5):406-12. PubMed ID: 20502014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Efficacy of Transdermal Rivastigmine in Mild to Moderate Alzheimer's Disease with Concomitant Small Vessel Cerebrovascular Disease: Findings from an Open-Label Study.
    Yatawara C; Zailan FZ; Chua EV; Lim LLH; Silva E; Wang JS; Ng A; Ng KP; Kandiah N
    Clin Interv Aging; 2021; 16():301-309. PubMed ID: 33642856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease.
    Winblad B; Grossberg G; Frölich L; Farlow M; Zechner S; Nagel J; Lane R
    Neurology; 2007 Jul; 69(4 Suppl 1):S14-22. PubMed ID: 17646619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating high-dose rivastigmine patch in severe Alzheimer's disease: analyses with concomitant memantine usage as a factor.
    Grossberg GT; Farlow MR; Meng X; Velting DM
    Curr Alzheimer Res; 2015; 12(1):53-60. PubMed ID: 25523430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of higher dose 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in patients with mild-to-moderate Alzheimer's disease.
    Grossberg G; Cummings J; Frölich L; Bellelli G; Molinuevo JL; Krahnke T; Strohmaier C
    Am J Alzheimers Dis Other Demen; 2013 Sep; 28(6):583-91. PubMed ID: 23982674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.
    Bartorelli L; Giraldi C; Saccardo M; Cammarata S; Bottini G; Fasanaro AM; Trequattrini A;
    Curr Med Res Opin; 2005 Nov; 21(11):1809-18. PubMed ID: 16307702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of switching to the rivastigmine transdermal patch from oral cholinesterase inhibitors: a naturalistic prospective study in Alzheimer's disease.
    Cagnin A; Cester A; Costa B; Ermani M; Gabelli C; Gambina G;
    Neurol Sci; 2015 Mar; 36(3):457-63. PubMed ID: 25394739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm²) in Alzheimer's disease.
    Cummings J; Froelich L; Black SE; Bakchine S; Bellelli G; Molinuevo JL; Kressig RW; Downs P; Caputo A; Strohmaier C
    Dement Geriatr Cogn Disord; 2012; 33(5):341-53. PubMed ID: 22796905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rivastigmine patch for treatment of Alzheimer's disease in clinical practice in Thailand.
    Kulkantrakorn K; Tanyakitpisal P; Towanabut S; Dejthevaporn C; Rangseekajee P; Pongpakdee S; Laptikultham S; Rodprasert K; Setthawatcharawanich S; Thinkhamrop B
    Psychogeriatrics; 2013 Mar; 13(1):1-8. PubMed ID: 23551405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of vascular risk factors on the efficacy of rivastigmine patch and capsule treatment in Alzheimer's disease.
    Farlow MR; Doraiswamy PM; Meng X; Cooke K; Somogyi M
    Dement Geriatr Cogn Dis Extra; 2011 Jan; 1(1):150-62. PubMed ID: 22163241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
    Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
    Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effectiveness of rivastigmine patch or capsule for mild-to-severe Alzheimer's disease: a meta-analysis.
    Su J; Liu Y; Liu Y; Ren L
    Expert Rev Neurother; 2015; 15(9):1093-103. PubMed ID: 26289489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.